Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751165 | 1.00 | PPARG (0.54) | PPARGEPHX2NOS3NOS1NOS2 | |
| SCHEMBL5750744 | 0.91 | EPHX2 (0.49) | PPARGEPHX2NOS3NOS1NOS2 | |
| SCHEMBL5748807 | 0.91 | EPHX2 (0.54) | PPARGEPHX2MDM2MMP8MAPT | |
| SCHEMBL5752445 | 0.90 | EPHX2 (0.50) | PPARGEPHX2PPARAMDM2MMP8 | |
| SCHEMBL5753587 | 0.89 | PPARG (0.53) | PPARGEPHX2PPARAMDM2GSK3B | |
| SCHEMBL5752412 | 0.89 | PPARG (0.52) | PPARGEPHX2NOS3NOS1NOS2 | |
| SCHEMBL5752947 | 0.88 | EPHX2 (0.52) | PPARGEPHX2PPARA | |
| SCHEMBL5750614 | 0.88 | PPARG (0.51) | PPARGEPHX2PPARAGSK3BMMP8 | |
| SCHEMBL5750586 | 0.87 | PPARG (0.51) | PPARGEPHX2PPARAMDM2MMP8 | |
| SCHEMBL5752663 | 0.86 | MDM2 (0.60) | MDM2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PPARG 905/4885EPHX2 1434/4885NOS3 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.